Henry Ford Health

Henry Ford Health Scholarly Commons
Emergency Medicine Articles

Emergency Medicine

5-4-2022

Immuno-Thrombotic Complications of COVID-19: Implications for
Timing of Surgery and Anticoagulation
Connor M. Bunch
Ernest E. Moore
Hunter B. Moore
Matthew D. Neal
Anthony V. Thomas

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/
emergencymedicine_articles

Authors
Connor M. Bunch, Ernest E. Moore, Hunter B. Moore, Matthew D. Neal, Anthony V. Thomas, Nuha
Zackariya, Jonathan Zhao, Sufyan Zackariya, Toby J. Brenner, Margaret Berquist, Hallie Buckner, Grant
Wiarda, Daniel Fulkerson, Wei Huff, Hau C. Kwaan, Genevieve Lankowicz, Gert J. Laubscher, Petrus J.
Lourens, Etheresia Pretorius, Maritha J. Kotze, Muhammad S. Moolla, Sithembiso Sithole, Tongai G.
Maponga, Douglas B. Kell, Mark D. Fox, Laura Gillespie, Rashid Z. Khan, Christiaan N. Mamczak, Robert
March, Rachel Macias, Brian S. Bull, and Mark M. Walsh

REVIEW
published: 04 May 2022
doi: 10.3389/fsurg.2022.889999

Immuno-Thrombotic Complications
of COVID-19: Implications for Timing
of Surgery and Anticoagulation
1

Edited by:
Philip Frank Stahel,
Rocky Vista University, United States
Reviewed by:
Robert W. Cross,
University of Texas Medical Branch at
Galveston, United States
Paolo Bernante,
University of Bologna, Italy
*Correspondence:
Mark M. Walsh
markwalshmd@gmail.com
†

Deceased

Speciality section:
This article was submitted to Visceral
Surgery, a section of the journal
Frontiers in Surgery
Received: 04 March 2022
Accepted: 05 April 2022
Published: 04 May 2022
Citation:
Bunch CM, Moore EE, Moore HB,
Neal MD, Thomas AV, Zackariya N,
Zhao J, Zackariya S, Brenner TJ,
Berquist M, Buckner H, Wiarda G,
Fulkerson D, Huff W, Kwaan HC,
Lankowicz G, Laubscher GJ,
Lourens PJ, Pretorius E, Kotze MJ,
Moolla MS, Sithole S, Maponga TG,
Kell DB, Fox MD, Gillespie L,
Khan RZ, Mamczak CN, March R,
Macias R, Bull BS and Walsh MM
(2022) Immuno-Thrombotic
Complications of COVID-19:
Implications for Timing of Surgery and
Anticoagulation.
Front. Surg. 9:889999.
doi: 10.3389/fsurg.2022.889999

Frontiers in Surgery | www.frontiersin.org

2

2

3

Connor M. Bunch , Ernest E. Moore , Hunter B. Moore , Matthew D. Neal , Anthony
4
4
5
5
5
V. Thomas , Nuha Zackariya , Jonathan Zhao , Sufyan Zackariya , Toby J. Brenner ,
5
5
5
4,6
4,6
Margaret Berquist , Hallie Buckner , Grant Wiarda , Daniel Fulkerson , Wei Huff ,
7
5
8
8
Hau C. Kwaan , Genevieve Lankowicz , Gert J. Laubscher , Petrus J. Lourens ,
9,13
10
11
11
Etheresia Pretorius , Maritha J. Kotze , Muhammad S. Moolla , Sithembiso Sithole ,
12
9,13,14
4
15
16
Tongai G. Maponga , Douglas B. Kell
, Mark D. Fox , Laura Gillespie , Rashid Z. Khan ,
4,17
18
4,19
20†
Christiaan N. Mamczak , Robert March , Rachel Macias , Brian S. Bull
4,5
and Mark M. Walsh *
1

Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, United States, 2Department of Surgery, Ernest E. Moore
Shock Trauma Center at Denver Health, Denver, CO, United States, 3Pittsburgh Trauma Research Center, University of
Pittsburgh Medical Center, Pittsburgh, PA, United States, 4Indiana University School of Medicine South Bend Campus, Notre
Dame, IN, United States, 5Department of Internal Medicine, Saint Joseph Regional Medical Center, Mishawaka, IN, United
States, 6Department of Neurosurgery, Saint Joseph Regional Medical Center, Mishawaka, IN, United States, 7Division of
Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United
States, 8Mediclinic Stellenbosch, Stellenbosch, South Africa, 9Department of Physiological Sciences, Stellenbosch University,
Stellenbosch, South Africa, 10Division of Chemical Pathology, Department of Pathology, Faculty of Medicine and Health
Sciences, Stellenbosch University and National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa,
11
Division of General Medicine, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and
Tygerberg Hospital, Cape Town, South Africa, 12Division of Medical Virology, Faculty of Medicine and Health Sciences,
Stellenbosch University, Cape Town, South Africa, 13Department of Biochemistry and Systems Biology, Institute of Systems,
Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom, 14The
Novo Nordisk Foundation Centre for Biosustainability, Technical University of Denmark, Kgs. Lyngby, Denmark, 15Department
of Quality Assurance and Performance Improvement, Saint Joseph Regional Medical Center, Mishawaka, IN, United States,
16
Department of Hematology, Michiana Hematology Oncology, Mishawaka, IN, United States, 17Department of Orthopaedic
Trauma, Memorial Hospital South Bend, South Bend, IN, United States, 18Department of Cardiothoracic Surgery, St. Joseph
Regional Medical Center, Mishawaka, IN, United States, 19Department of Plastic and Reconstructive Surgery, St. Joseph
Regional Medical Center, Mishawaka, IN, United States, 20Department of Pathology and Human Anatomy, Loma Linda
University School of Medicine, Loma Linda, CA, United States

Early in the coronavirus disease 2019 (COVID-19) pandemic, global governing bodies prioritized
transmissibility-based precautions and hospital capacity as the foundation for delay of elective
procedures. As elective surgical volumes increased, convalescent COVID-19 patients faced
increased postoperative morbidity and mortality and clinicians had limited evidence for
stratifying individual risk in this population. Clear evidence now demonstrates that those
recovering from COVID-19 have increased postoperative morbidity and mortality. These data—
in conjunction with the recent American Society of Anesthesiologists guidelines—offer the
evidence necessary to expand the early pandemic guidelines and guide the surgeon’s
preoperative risk assessment. Here, we argue elective surgeries should still be delayed on a
personalized basis to maximize postoperative outcomes. We outline a framework for stratifying
the individual COVID-19 patient’s ﬁtness for surgery based on the symptoms and severity of
acute or convalescent COVID-19 illness, coagulopathy assessment, and acuity of the surgical
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procedure. Although the most common manifestation of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection is COVID-19 pneumonitis, every system in the body is
potentially afﬂicted by an endotheliitis. This endothelial derangement most often manifests as a
hypercoagulable state on admission with associated occult and symptomatic venous and arterial
thromboembolisms. The delicate balance between hyper and hypocoagulable states is deﬁned by
the local immune-thrombotic crosstalk that results commonly in a hemostatic derangement
known as ﬁbrinolytic shutdown. In tandem, the hemostatic derangements that occur during acute
COVID-19 infection affect not only the timing of surgical procedures, but also the incidence of
postoperative hemostatic complications related to COVID-19-associated coagulopathy (CAC).
Traditional methods of thromboprophylaxis and treatment of thromboses after surgery require a
tailored approach guided by an understanding of the pathophysiologic underpinnings of the
COVID-19 patient. Likewise, a prolonged period of risk for developing hemostatic complications
following hospitalization due to COVID-19 has resulted in guidelines from differing societies that
recommend varying periods of delay following SARS-CoV-2 infection. In conclusion, we propose
the perioperative, personalized assessment of COVID-19 patients’ CAC using viscoelastic
hemostatic assays and ﬂuorescent microclot analysis.
Keywords: COVID-19, elective surgical procedure, immunothrombosis, obstetrics, orthopedic procedures, venous
thromboembolism, thrombophilia, ﬁbrinolysis

countries who underwent elective or emergency surgery
during October 2020 (10). Surgical patients with preoperative
SARS-CoV-2 infection were compared to those without
previous SARS-CoV-2 infection. There was a signiﬁcant
increase in postoperative pulmonary complications and
mortality in patients with a recent diagnosis of SARS-CoV-2
infection (10). The calculated 30-day mortality rates were
stratiﬁed by time between diagnosis of SARS-CoV-2 infection
and surgery (groups included those diagnosed 0–2, 3–4, 5–6,
and ≥7 weeks prior to surgery). For those patients without
SARS-CoV-2 infection, the adjusted 30-day mortality rate was
1.5%. For those patients diagnosed with SARS-CoV-2
infection, 30-day postoperative mortality rates were 9.1% for
0–2 weeks; 6.9% for 3–4 weeks; 5.5% for 5–6 weeks; and 2.0%
at ≥7 weeks between diagnosis and surgery. Surgery
performed ≥7 weeks after SARS-CoV-2 diagnosis was
associated with a similar mortality risk to baseline for controls
(odds ratio 1.5 [95%CI 0.9–2.1]). Further stratifying this
analysis to those patients with ongoing symptoms at time of
surgery, it was noted that even after a ≥7 week delay from
SARS-CoV-2 infection diagnosis, these symptomatic
convalescent patients had a higher mortality than patients
whose symptoms had resolved or who had been asymptomatic
at operation (6.0% for ongoing symptoms, vs. 2.4% for
resolved symptoms, vs. 1.3% for controls).
Consequently, the authors recommended that surgery be
delayed for at least seven weeks following SARS-CoV-2
infection, and concluded that patients with ongoing symptoms
at seven weeks may beneﬁt from even longer delay (10). A
recent multidisciplinary consensus statement aligned with
these study conclusions, stating that elective surgery should be
scheduled seven or more weeks after the diagnosis of COVID19 for patients with asymptomatic or transient SARS-CoV-2
infection, while patients with persistent symptoms (i.e., “Long
COVID”) remain at elevated risk for postoperative morbidity
and mortality even after seven weeks. It is therefore

INTRODUCTION: PERIOPERATIVE COVID19 AND POSTOPERATIVE MORBIDITY AND
MORTALITY
The global impact of the coronavirus disease 2019 (COVID-19)
pandemic on surgical procedures was unprecedented (1, 2). After
the induction of the national state of emergency in the United
States in March 2020, the Centers for Medicare and Medicaid
Services (CMS), the American College of Surgeons (ACS), and
other international surgical societies recommended postponing,
minimizing, and cancelling elective surgical procedures based
largely on SARS-CoV-2 transmissibility precautions (3–5).
During this time, there was a 50% reduction in the number of
surgical procedures performed relative to baseline (1). Five weeks
later, a joint recommendation was published that advised the
resumption of elective surgical procedures (6). As the demand
for elective procedures increased, clinicians were faced with a
growing number of patients still recovering from COVID-19, and
surgeons had little available evidence for the optimal timing of
surgery and postoperative prognosis for those recovering from
acute and/or convalescent COVID-19 illness (7).
As the pandemic continued and data accrued, postoperative
morbidity and mortality were conﬁrmed to be signiﬁcantly
higher for patients with perioperative COVID-19 infection (8).
Perioperative COVID-19 infection correlated with higher rates
of postoperative pulmonary complications and venous
thromboemboli (VTE) (e.g., pulmonary emboli [PE] and deep
venous thromboses [DVT]) (9). Notably, those with ongoing
symptoms at the time of operation—regardless of length from
diagnosis/onset of COVID-19 symptoms—have a signiﬁcantly
greater risk of VTE and associated mortality. VTE has been
independently associated with 30-day postoperative mortality
(odds ratio 5.4 [95%CI 4.3–6.7]) (9).
One prospective cohort study by the COVIDSurg
Collaborative evaluated >140,000 surgical patients from 116
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Breakthrough infections in vaccinated individuals have less
thrombotic risk and lower risk of severe illness (27). Following
the ASA guidelines, patients’ length of delay for surgery
should be based on the severity of illness regardless of
vaccination status.
The impact of COVID-19 on immune system-related
complications in surgical patients is a crosstalk between
immunology and coagulation at the level of the endothelium.
This is more than a theoretical concept; rather, it is an
important pathophysiologic understanding of the unique
challenges of operating on patients who have either recent or
remote infections with the SARS-CoV-2 virus. Few guidelines
exist concerning the timing and nature of this dual threat of
bleeding and clotting that occur in a surgical patient with
COVID-19 (28, 29). This review will address the
pathophysiologic underpinnings of COVID-19 as it relates to
surgical timing and thromboprophylaxis, followed by a speciﬁc
application of these immune-thrombotic changes to
perioperative and postoperative management of patients.

recommended to stratify patient risk in delaying surgery beyond
seven weeks on a personalized basis (11). In one systematic
review including >250,000 patients, more than half had
post-acute sequelae of COVID-19 at six months follow-up
(12). Clearly, there is a signiﬁcant need to risk stratify this
patient population on an individualized basis.
The most recent American Society of Anesthesiologists
(ASA) and Anesthesia Patient Safety Foundation (APSF) joint
recommendation for the delay of surgery have been divided
into four blocks of time based upon the symptoms and
severity of acute COVID-19 illness:
“Four weeks for an asymptomatic patient or recovery from
only mild, non-respiratory symptoms
• Six weeks for a symptomatic patient (e.g., cough, dyspnea)
who did not require hospitalization
• Eight to 10 weeks for a symptomatic patient who is diabetic,
immunocompromised, or hospitalized
• Twelve weeks for a patient who was admitted to an intensive
care unit due to COVID-19 infection”
•

The ASA and APSF joint recommendation further states: “These
timelines should not be considered deﬁnitive; each patient’s
preoperative risk assessment should be individualized,
factoring in surgical intensity, patient co-morbidities, and the
beneﬁt/risk ratio of further delaying surgery” (13). Speciﬁcally,
these recommendations have not considered the differing
degrees of coagulopathy associated with COVID-19 variants.
Additionally, there is little guidance on elective surgery for
patients afﬂicted with Long COVID, and there are few
proposals for preoperative laboratory measurements (e.g.,
D-dimer, ﬁbrinogen, ferritin, lactate dehydrogenase (LDH),
and other clinical and laboratory markers of severity of
disease) to guide surgeons and anesthesiologists for the
appropriate timing of surgery (14, 15).
Likewise, sparse guidance exists for the postoperative
thromboprophylaxis of this patient group. In a large study of
11,249 patients from the ﬁrst COVID-19 surge in the Spring
of 2020 in New York City, 1.7% of all patients discharged
from the hospital had VTE or arterial thromboembolism (16).
This study also reported that prophylactic anticoagulation
with either enoxaparin or rivaroxaban engenders a 46%
reduction in clotting disorders (16). However, the unique
pathophysiological aspect of COVID-19 pneumonitis is that
these patients may bleed and clot at the same time when
anticoagulated (17). It was reported that 1.73% of discharged
patients suffered major bleeding within 90 days of discharge
while only 13.2% of the entire cohort was administered
thromboprophylaxis (16).
Together these ﬁndings offer surgeons the opportunity to
familiarize themselves with the unique hemostatic
derangement of CAC affecting postoperative outcomes
worldwide. A basic ﬂow chart for triaging acute and
convalescent COVID-19 patients based upon recent ASA and
surgical guidelines for the timing of surgery and postoperative
VTE prophylaxis is presented in Figure 1. Clear data
demonstrates unvaccinated individuals with COVID infection
procure a higher risk of thrombosis and more severe illness.

Frontiers in Surgery | www.frontiersin.org

COVID-19-ASSOCIATED COAGULOPATHY
(CAC)
Recent consensus and guidelines exist, but they lack granularity
to assist the surgeon for optimizing the timing of elective
surgery and guiding postoperative thromboprophylaxis for
their individual convalescent COVID-19 patients. The longterm effects of COVID-19 infection are still under
investigation. Hence, there are limited studies or speciﬁc
guidelines aiding the surgeon in weighing risks and beneﬁts of
elective surgery for patients post-recovery from COVID-19.
Persistent complications of COVID-19 infection after recovery
are a product of the vast endothelial damage induced by
SARS-CoV-2 (29). It is pertinent for the surgeon and
anesthesiologist to understand the mechanisms of this
endotheliitis to individualize care for their convalescent
COVID-19 patients in this time of limited evidence-based
guidance.

Pathophysiology of CAC: A Labile Balance
Between Fibrinolysis and Fibrinolytic
Shutdown
Immuno-thrombosis is often described as the dysregulated
interaction between innate immunity and coagulation (30–32).
A reported 30-80% of COVID-19 ICU patients endure
thrombotic complications during their clinical course (33–36).
The most common thrombotic complication in COVID-19
patients is VTE, which occurs in 15-85% of patients (37).
Although the exact mechanism behind CAC is poorly
understood, endotheliitis likely incites the hypercoagulable
state (Figure 2) (38–42). The SARS-CoV-2 virus directly
invades endothelial cells through the angiotensin converting
enzyme 2 (ACE2) receptor. This leads to localization of viral
inclusion bodies in the lungs, liver, small intestines, and
kidneys, shedding of endothelial glycocalyx proteins, and
decreases in the level of heparanase-2. This results in a
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FIGURE 1 | COVID-19 patient surgical ﬁtness ﬂow chart. The surgeon assesses the acuity of the procedure using the specialty-speciﬁc Elective Surgery Acuity
Scale (ESAS). If the procedure is of low/intermediate acuity and can be delayed, the length of delay may follow American Society of Anesthesiologists’
recommendations. After the delay, timing of surgery is a function of both the necessity of surgery and the degree of recovery of respiratory and hemostatic
derangement post-COVID-19. Post-operatively, due to a high degree of hypercoagulability in many convalescent COVID-19 patients, standard pharmacologic VTE
prophylaxis may be considered in all these patients. Created using BioRender.com. *Cardiorespiratory symptoms such as shortness of breath, chest pain, and
fatigue are common in patients with convalescent COVID-19 (12, 13, 18, 19). Coagulopathy, including both hyper and hypocoagulable states, should be assessed
pre- and post-operatively using ﬁbrinogen levels, platelet count, and viscoelastic hemostatic assays (e.g., thromboelastography (TEG) and rotational
thromboelastometry (ROTEM)). The deﬁnition of hyper and hypocoagulability are a function of institutional preference. **This is not an exhaustive list of anticoagulant
agents, nor a comprehensive dosing regimen. For inpatients acutely ill with COVID-19, those with VTE, those who undergo emergent surgery, or those at risk for
hemorrhage, personalized titration of anticoagulation with adjunctive viscoelastic hemostatic assays is recommended (17, 20–23). VTE prophylaxis for postoperative
patients with acute or convalescent COVID-19 is not speciﬁcally addressed in recent expert consensus statements or society recommendations (24–26). As such,
this recommendation is the opinion of the authors and should be judiciously applied taking into account each individual patient’s risk and beneﬁt to anticoagulant therapy.
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FIGURE 2 | COVID-19-associated coagulopathy (CAC) and Fibrinolytic Shutdown. (1) The SARS-CoV-2 Spike protein binds with angiotensin converting
enzyme 2 (ACE2), which causes internalization of the receptor and virus into the host cell. (2) In turn, ACE2 is not available for breakdown of angiotensin II (AT-II)
leading to its build-up. AT-II causes subsequent lung injury and increases in plasminogen activated inhibitor 1 (PAI-1). Angiotensin I-7 (AT-I-7) and angiotensin I-9
(AT-I-9) are increased by other pathways involving activated platelets, but also lead to increased levels of PAI-1. (3) Increased circulating PAI-1 leads to
ﬁbrinolytic shutdown, a hypercoagulable state characterized by increased ﬁbrin deposition and thrombus formation. (4) Among other mechanisms, widespread
endotheliitis and microthrombosis can cause multi-organ injury in patients with severe COVID-19 illness. This exacerbates the acute inﬂammatory response, often
causing a cytokine storm and worsening immuno-thrombosis. Inﬂammatory cytokines activate Factor XII (FXII), which subsequently increases bradykinin levels.
Bradykinin increases tissue plasminogen activator (tPa) levels. (5) This subacute rebalancing of the ﬁbrinolytic system predisposes the COVID-19 patient to both
thrombosis and hemorrhage as a function of local endothelial derangement. This is particularly the case for hospitalized COVID-19 patients who are
anticoagulated; these patients’ anticoagulant regimen must be judiciously titrated on a personalized basis (17, 29, 31). The spectrum of ﬁbrinolysis is depicted as
a balance whereby the predominate hypercoagulable ﬁbrinolytic shutdown phenotype is portrayed as a balance with high levels of PAI-1, thrombin activatable
ﬁbrinolysis inhibitor (TAFI), ﬁbrinogen, D-dimer, and lower levels of tPa and plasmin. The opposite occurs at the opposite end of the ﬁbrinolysis spectrum when
ﬁbrinolysis predominates, which occurs much less frequently in CAC. Created using BioRender.com
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The TEG/ROTEM evaluates the patient’s position along the
hemostatic spectrum from hypo to hypercoagulable states. The
tracings resemble a shovel, whereby the length of the handle
reﬂects coagulation factor competence, the slope of the blade
reﬂects ﬁbrinogen concentration, the thickness of the blade
reﬂects clot contraction mediated by ﬁbrin-platelet interaction,
and the tapering end of the blade represents ﬁbrinolysis.
Therefore, a characteristic early COVID-19 patient with a
hypercoagulable state presents with a short handle, a steep
slope, and a thick blade with no tapering of the blade, which
represents enhanced effect of coagulation factors, increased
ﬁbrinogen concentration, increased ﬁbrin/platelet function,
and ﬁbrinolytic shutdown. At the other end of the spectrum
lies the hypocoagulable state as manifested by a long handle,
ﬂat slope, thin blade, with signiﬁcant tapering. In Figure 3,
examples of this paradigm are represented along various
stages of this spectrum of coagulopathies associated with
COVID-19.
The hypercoagulability of COVID-19 patients is clearly
complex and multifactorial, but understanding these complex
mechanisms allows for the pursuit of speciﬁc treatment
strategies to improve patient outcomes. Management is
complicated because of ﬁbrinolytic shutdown due to the
reduction of natural ﬁbrinolysis at the level of the endothelium.
While a multitude of studies have shown the detrimental effect
of ﬁbrinolytic shutdown on COVID-19 patient outcomes,
bleeding complications such as gastrointestinal bleeding and
hemorrhagic stroke are also common, especially in patients on
therapeutic anticoagulation (17, 79, 80, 82–86). These patients
tend to clot and bleed at the same time, a function of the
“rollercoaster” phenomenon (77).

progression from normal hemostasis to a relatively
antiﬁbrinolytic state (31, 38, 43–45). The SARS-CoV-2 viral
saturation of ACE2 increases circulating levels of angiotensin
II, leading to increased production of the important
antiﬁbrinolytic mediator, plasminogen activator inhibitor 1
(PAI-1) (46–48). Elevated PAI-1 and thrombin-activatable
ﬁbrinolysis inhibitor (TAFI) levels in the alveolar space have
been identiﬁed in COVID-19 patients (46, 49–51). Elevated
tissue plasminogen activator (tPa) levels have also been noted
in COVID-19 patients. This tPa release may be due to
malperfusion secondary to microvascular ﬁbrin deposition.
Despite this increase in tPa, pro-thrombosis persists in these
patients, suggesting that elevated PAI-1 and TAFI overwhelm
the action of tPa, resulting in microvascular deposition of
ﬁbrin (52). These factors contribute to the disruption of the
tightly regulated balance between thrombosis and ﬁbrinolysis
in COVID-19 patients, leading to what is known as
“ﬁbrinolytic shutdown” (17, 46, 50, 52–58). When combined
with elevated thrombin generation, it leads to adverse
complications such as a type of adult respiratory distress
syndrome (ARDS), multisystem organ failure, and mortality
(29, 59–62). This unique type of ARDS is often associated
with a localized hypercoagulability of the pulmonary
vasculature due to abnormal deposition of ﬁbrin and
development of microthrombosis (63–66). Postmortem
analyses conﬁrm a similar presentation in patients with
COVID-19-induced
ARDS
(67–70).
This
localized
hypercoagulability is partially induced by inﬂammation of
tissue, leading to elevated tissue factor (TF) production by
epithelial cells and alveolar macrophages which results in the
deposition of ﬁbrin and the development of microthrombosis
(46, 71). Thromboses are additionally potentiated by a
deﬁcient ﬁbrinolytic response primarily induced by the
overexpression of PAI-1 from activated platelets and
endothelial cells (31, 72, 73).
Primary hemostasis, which is accomplished via activated
platelets at the site of endothelial injury, contributes to the
hypercoagulable
state
of
the
COVID-19
patient.
Overwhelming platelet activation is driven by many stimuli,
and signiﬁcantly facilitated by increased levels of von
Willebrand Factor (VWF), as well as activation of the
enzymatic (intrinsic) clotting pathway. COVID-19 patients
have increased activation of circulating platelets as
demonstrated by elevated soluble P-selectin as well as markers
for endothelial activation (74). A direct stimulatory role of
SARS-CoV-2 Spike protein on the COVID-19 patient’s
platelets has also been described (75). Severe COVID-19
illness correlates not just with platelet activation but is also
associated with enhanced platelet-monocyte aggregation.
Finally, ICU admitted COVID-19 patients’ platelets induce Pselectin and αIIb/β3-dependent monocyte TF expression
which may augment inﬂammation and hypercoagulability (76).
Together, these aberrancies in hemostasis mediated by
platelets and reduced ﬁbrinolysis (documented by whole blood
viscoelastic hemostatic assays [VHAs], thromboelastography
[TEG] and rotational thromboelastometry [ROTEM])
inevitably lead to uncontrollable hypercoagulopathy (76–78).

Frontiers in Surgery | www.frontiersin.org

Timing of Elective Surgery for Acute and
Convalescent COVID-19 Patients
Even for those patients without comorbidities or illness
requiring hospitalization, a large number of convalescent
COVID-19 patients at four months post-infection are reported
to have one or more residual organ system impairments as
deﬁned by quantitative magnetic resonance imaging (MRI) T1
mapping (12, 87). This phenomenon is termed Long COVID
(or post-acute sequelae of COVID-19 [PASC]) and can
involve any organ system (88). Hypercoagulability and VTE
have been described as potential complications in Long
COVID patients (88). In the convalescent COVID-19 patient,
it is important to understand that the timing of surgery is a
function of where the patient lies within the context of their
individual immuno-thrombotic state (77).
Further research is necessary for determining potential
biomarkers which may allow surgeons to weigh the risks and
beneﬁts of elective surgery. Multiple studies have shown
persistently elevated D-dimer, ﬁbrinogen, C-reactive protein
(CRP), interleukin (IL)-4, IL-6, tumor necrosis factor (TNF)α, interferon (IFN)-γ-induced protein 10, factor VIII, VWF,
and plasma soluble thrombomodulin in patients up to six
months post-recovery from COVID-19 (81, 89–94),
indicating that these may serve as potential biomarkers
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FIGURE 3 | The “rollercoaster” phenomenon of COVID-19-associated coagulopathy. The three stages of COVID-19-associated coagulopathy and their
relationship to the immuno-thrombotic derangement caused by the cytokine storm are represented above by viscoelastic hemostatic assays (e.g.,
thromboelastography [TEG]). (A) represents the acute ﬁbrinolytic shutdown phenotype (short R, steep α, thick MA, no lysis). (B) represents the eventual evolution
to a normal physiologic ﬁbrinolytic phenotype (normal R, α, MA, and LY30). (C) represents the TEG in evolution without anticoagulation and the subacute
recovery stage where the patient is less hypercoagulable (parameters intermediate between acute and remote). (D) represents the patient with or without
anticoagulant with a hypocoagulopathic phenotype due to hypoﬁbrinogenemia and/or a thrombocytopenia in spite of persistent ﬁbrinolytic shutdown (long R, ﬂat
α, narrow MA, no lysis) (17, 20, 77, 79–81). Created using Adobe Illustrator.

signiﬁcant thrombophilia with ﬁbrinolysis shutdown being a
primary component, regulated by higher circulating levels of
antiﬁbrinolytic factors, namely PAI-1 and TAFI. Yet,
coagulation is a rigorously regulated process: ﬁbrinolytic and
thrombotic pathways are continuously competing against each
other such that neither hemorrhage nor thrombosis is favored
under normal physiological conditions (98). Therapeutic
strategies for COVID-19 patients that utilize these ﬁndings,
including the use of ﬁbrinolytics, have been under examination
and show potential for improving patient outcomes. For
patients being treated with COVID-19, therapeutic
anticoagulation is the standard regimen for patients with
macrothrombosis. Furthermore, the use of anticoagulant
heparinoids is advised for all COVID-19 patients (99). The use
of tPa has been suggested for patients with severe ARDS
caused by COVID-19 (100). In these studies, the use has been
late in the disease course. Theoretically, if tPa is used earlier

for assessing the risk of postoperative complications.
Hypercoagulability markers are often associated with
postoperative complications in non-COVID-19 perioperative
settings (e.g., PAI-1, TAFI, increased ﬁbrinogen and platelet
counts) (7, 95–97). Research on these and other biomarkers
in assessing postoperative morbidity and mortality in
convalescent COVID-19 patients undergoing elective surgery,
however, is lacking. Future studies are required in order to
determine the most prognostic biomarkers for evaluating this
patient population (88).

Treatment and Thromboprophylaxis for the
Postoperative COVID-19 Patient
COVID-19 and the subsequent damage to endothelial cells result
in a progression from hemostasis to a relatively prothrombotic/
antiﬁbrinolytic state (31, 38, 43–45). Clinical data demonstrate
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during the hypercoagulable stages of the disease, the ﬁbrinolytic
and therapeutic effect may be greater than those reported in the
recent literature. Also, when administered later in the course of
the disease—as the cytokine storm recedes—the patients may
be prone to hemorrhage similar to anticoagulated COVID-19
patients (17, 101).
Therapeutic anticoagulation and thromboprophylaxis for the
hospitalized COVID-19 surgical patient vary substantially.
Recommendations have been made from adherence to
standard VTE prophylactic guidance to intermediate or
therapeutic dosing for moderately ill COVID-19 patients
(85, 86). The preferred agents have been enoxaparin with antiXa monitoring or unfractionated heparin with either activated
partial thromboplastin time (aPTT) or anti-Xa guidance. This
heterogeneity is based on large multiplatform randomized
controlled trials (RCTs) as well as society consensus
statements. Recent guidelines and consensus statements have
considered conditional support for therapeutic and/or
intermediate heparinoid thromboprophylaxis for moderately ill
COVID-19 patients not requiring high-ﬂow oxygen (Table 1)
(24–26, 85, 86, 99, 102–104). The importance of this
foundational literature has been highlighted by observations
that clinicians ﬁnd it difﬁcult to practice medicine during the
COVID-19 pandemic bereft of RCTs to guide treatment (105).
Therefore, reliance on categorization of hemostatic phenotype
by VHAs fulﬁlls the criteria of personalized-based medicine as
a guidance for anticoagulation and thromboprophylaxis for
the COVID-19 surgical patient.
For elective cases, a high incidence of patients discharged
from the hospital have VTEs within 90 days of discharge from
COVID-19 (16). In addition, a subsection of the population
who have COVID-19 and have undergone surgery have a
markedly elevated rate of VTEs (9). Because of the absence of
speciﬁc RCTs recommending postoperative DVT prophylaxis
in this group of patients, use of Elective Surgery Acuity Scale
(ESAS) guidelines as well as co-morbidities and adjunctive
VHA analysis would allow for postoperative DVT prophylaxis
similar to that which has been recommended for the postCOVID discharged patient. Speciﬁcally, the recommendations

vary from 10 mg rivaroxaban for 35 days, 2.5 mg apixaban
b.i.d. for 35 days, or for patients with normal renal function,
40 mg enoxaparin for 35 days (102, 106, 107). Speciﬁc comorbid analysis using conventional coagulation tests with
adjunctive TEG-guided anticoagulation for COVID-19 patients
with and without macrothrombosis has demonstrated the
ability of the TEG to assist in the prediction of bleeding and
clotting in this group of patients (17, 108). Similarly, the large
RCTs which have demonstrated therapeutic beneﬁt of
heparinoids in moderately ill COVID-19 patients would be
reﬁned by the addition of VHAs to guide anticoagulant
therapy (17, 85, 86, 109).
As has been shown, so-called “intermediate” and therapeutic
anticoagulation has been found to protect patients with
moderately severe COVID-19 pneumonitis (86). Surgeons will
ﬁnd themselves during the acute and subacute period
considering emergent and semi-emergent procedures for
patients on anticoagulation not just for known macrothromboses
but also for the speciﬁc antiviral and antiinﬂammatory
functions of heparinoids in these patients (85, 86, 109). In
addition to conventional coagulation tests, anticoagulation for
these patients is facilitated by adjunctive hemostatic
monitoring with VHAs (17, 20–22).
The sequelae of Long COVID may be a function of residual
endothelial damage from the SARS-CoV-2 endothelial cell
invasion (88, 110). As such, thromboprophylaxis for
postoperative convalescent COVID-19 patients should draw
from strategies to manage acute COVID-19 patients along
with the strategies for non-COVID-19 patients undergoing
elective surgery.

Viscoelastic Hemostatic Assays and
Plasma Fluorescent Microclot Analysis as
Precision-based Tools to Contextualize
COVID-19-associated Immuno-thrombosis
Surgeons—because of their more than half century experience
with TEG/ROTEM to diagnose and treat coagulopathies in
liver transplantation, cardiac surgery, and trauma—have been

TABLE 1 | Salient society recommendations on anticoagulant dosing for acute COVID-19 patients.
Society

Outpatient

Inpatient

Intensive Care Unit

Post-discharge

American Society of
Hematology (February 2,
2022) (24)

Thromboprophylaxis not
recommended

For patients without VTE, standard
prophylactic dose with LMWH or UFH

For patients without VTE,
standard prophylactic
dose with LMWH or UFH

Thromboprophylaxis not
recommended

American College of Chest
Physicians (CHEST)
Guideline (February 12,
2022) (25)

Not addressed

Conditional recommendation: For patients
without VTE, therapeutic dose with LMWH or
UFH

For patients without VTE,
standard prophylactic
dose with LMWH or UFH

Not addressed

National Institutes of Health
(NIH) Guidelines (February
24, 2022) (26)

Not addressed

Therapeutic dose heparin only for patients
hospitalized on low-ﬂow oxygen
For hospitalized patients without VTE and not
requiring oxygen or requiring high-ﬂow device
or NIV, standard prophylactic dose with
LMWH or UFH

For patients without VTE,
standard prophylactic
dose with LMWH or UFH

Thromboprophylaxis not
recommended

Abbreviations: LMWH, low molecular weight heparin; UFH, unfractionated heparin; VTE, venous thromboembolism.
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at the forefront of pathophysiologic investigations of CAC (111).
Because of surgeons’ historical experience on the intricacies of
hemostasis, surgeons have employed TEG/ROTEM to guide
and personalize anticoagulation during the COVID-19
pandemic (20–22, 28, 29, 101, 112). TEG/ROTEM have also
been used to proﬁle postoperative patients at risk for VTE (23,
113–116). This background in using TEG/ROTEM to predict
a patient’s ﬁbrinolytic phenotype prepares the surgeon to
manage CAC patients. Given the signiﬁcant variation in risk
of the development of either a hypocoagulopathic- or
hypercoagulopathic-related complication in the perioperative
period as a function of the severity of COVID-19 illness, it
is difﬁcult to rely on arbitrary standards regarding the
timing of surgery and the nature of anticoagulation and
thromboprophylaxis in this group of patients (17, 28, 29, 31, 108).
The recent evolution of the less virulent but more infectious
variants, such as the omicron (B.1.1.529), may render guidelines
regarding the timing and nature of therapeutic anticoagulation
and thromboprophylaxis for the surgical patient less
applicable. Although there is no data directly demonstrating
lower risk of thrombosis in patients infected with omicron
versus other more virulent variants, thrombosis risk in
COVID-19 patients is in large part a function of illness
severity (117, 118). By logical extension of this evidence, it is
likely omicron infection carries less thrombotic risk compared
to more virulent variants such as alpha or delta. Age, comorbidities, and overall clinical picture are paramount to
consider when deciding to what degree the individual patient
should be anticoagulated. There are no plasma-based
laboratory tests which allow for prediction of the likelihood of
perioperative complications regarding coagulation for the
surgical patient with either acute or remote COVID-19
infection. Historically, VHAs have been used to predict both
bleeding and clotting in patients undergoing liver
transplantation, cardiac surgery, trauma surgery, and most
recently, bleeding and clotting obstetric patients. Most
recently, adjunctive TEG has demonstrated prediction of VTE
in critically ill COVID-19 patients (20–23). However,
categorizing patients’ ﬁbrinolytic and coagulopathic phenotype
with TEG/ROTEM, as has been done by surgeons for decades,
may allow the surgeon to better predict the development of
perioperative clot and to manage pre- and post-surgical clots
more effectively in the COVID-19 patient. In addition, platelet
activation can be graded with plasma microclot density
analysis, which has demonstrated that Long COVID patients
have a persistent coagulopathy and increased microclot
formation (119). Together, TEG/ROTEM with microclot
analysis may predict the surgical patient’s position in the
hemostatic and ﬁbrinolysis spectrum in the absence of
evidenced biomarkers. Figure 3 illustrates the ‘rollercoaster’
phenomenon of hospitalized COVID-19 patients as
characterized by TEG/ROTEM in the acute and subacute
periods, as well as the remote period after discharge (77).
Figure 4 provides a prototype spectrum of CAC wherein the
patient’s individual coagulopathy may be modiﬁed by the
COVID-19 variant and is characterized by TEG/ROTEM and
plasma microclot analysis. Studies are in progress regarding
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microclot analysis as an enhanced method of hemostatic
grading (78).

SURGICAL SOCIETIES’
RECOMMENDATIONS FOR THE COVID-19
PATIENT’S TIMING OF SURGERY AND
THROMBOPROPHYLAXIS
Emergency surgery in the acute period of COVID-19 infection
requiring hospitalization is associated with high mortality (8,
123). These increases in mortality have been observed across
various surgical specialties (123). As a result, there are surgical
specialty-speciﬁc recommendations regarding the timing of
surgery for patients with symptomatic and asymptomatic
SARS-CoV-2 infection. These recommendations are varied
and a function of institutional preference and expert
consensus. Table 2 and the text below summarizes the
literature and recommendations of the leading surgical and
obstetric organizations regarding the timing and administration
of thromboprophylaxis for patients with acute and remote
SARS-CoV-2 infection.

Obstetrics
Obstetricians have long experience with surgical interventions
on patients who have peripartum coagulopathies wherein the
patient may switch between hemorrhagic and thrombotic
phenotypes rapidly. Obstetricians have similar experience as
CAC with pathologies such as preeclampsia, Hemolysis,
Elevated Liver enzymes, and Low Platelets (HELLP)
syndrome, morbidly adherent placenta (MAP) and other
signiﬁcant diseases associated with the peripartum state (145–
156). This spectrum of disorders in the peripartum patient
allow pathophysiological comparison to the hemostatic
derangement of CAC in the nonpregnant surgical patient (29,
157). In each disease entity, there is endotheliitis that results
in an immuno-thrombotic crosstalk resulting in local
thrombosis and/or hemorrhage at the level of the inﬂamed
endothelium (17, 157). For example, prepartum patients with
preeclampsia must be given thromboprophylaxis to prevent
clotting, but during parturition, they are at higher risk for
bleeding, and again return to a hypercoagulable state
postpartum (157). In tandem, postpartum patients with
preeclampsia or other underlying risk factors for a
hypercoagulable state should be treated for at least six weeks
with thromboprophylaxis postpartum (146). Hence, discussion
of the obstetrical approaches to providing thromboprophylaxis
serves as an ideal foundation for describing the other surgical
disciplines with more straightforward pathophysiological
proclivities for the formation of perioperative clots.
International guidelines for thromboprophylaxis for women
who have undergone a C-section are heterogeneous in their
recommendations regarding the timing and duration of
thromboprophylaxis (146, 158).
In the United States and other countries, thromboprophylaxis
for women undergoing C-sections has been described by the
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FIGURE 4 | Prototype spectrum of COVID-19-associated coagulopathy used to assess the patient’s coagulopathy with thromboelastography (TEG) and
plasma microclot analysis. Shown above is an example of correlation between the most hypercoagulable delta (B.1.617.1) variant, intermediate hypercoagulable
omicron (B.1.1.529) variant, and physiologic TEGs with corresponding plasma microclot analyses. Using Thioﬂavin-T as a ﬂuorescent marker speciﬁcally for microclot
staining, ﬂuorescence microscopy demonstrates microclots in plasma with representative examples of different degrees of microclot formation as related to delta (A),
omicron (B), and physiologic (C) TEGs. Previously described, Stage 1 to 4 is a qualitative numerical scoring system where a score of 4 is given for signiﬁcant and
widespread microclot formation and a score of 1 is given for minimal microclot formation (78, 119). In this ﬁgure, delta variant (A) equals stage 4, omicron (nonhospitalized patient) (B) is stage 3, normal physiologic non-infected individual (C) is stage 2. A hypocoagulable state either from anticoagulation of the COVID-19
patient or due to naturally acquired disease from COVID-19-associated coagulopathy is stage 1 (not pictured). Patients with Long COVID also demonstrate
microclot formation, which may be used to assess platelet dysfunction and surgical candidacy in this group of patients (77, 78, 119). The omicron variant (BA.1
sub-lineage) was detected by polymerase chain reaction (PCR) based on S-gene target failure (SGTF) as a proxy for variant status (https://www.science.org/doi/
10.1126/science.abn4543) (120). The TaqPath COVID-19 Combo Kit® (Thermo Fisher Scientiﬁc) identiﬁes SARS-CoV-2 infections by detecting 3 viral gene
regions, E, RdRP, and N gene. The laboratory reported positive cycle threshold of 32 cycles for both the E gene, 35 for RdRP and 34 for the N gene. Positive N
gene with negative S gene (SGTF) is an acceptable proxy of the BA.1 variant when the gold-standard whole genome sequencing is not done. The PCR result
combined with reported case counts and known genomic epidemiology of the 4th wave in South Africa has been used to track changes in transmission over
time for the BA.1 variant (121, 122).

many organizations with speciﬁc references to pregnant
women (164–166).

American College of Obstetricians & Gynaecologists guidelines
that recommend thromboprophylaxis for all patients with Csections who have at least one major indication or two minor
indications for anticoagulation (159). The three major
indications are previous VTE, body mass index (BMI) > 35,
and thrombophilia. The minor indications are preeclampsia,
hypertension, diabetes, peripartum infection, and other
comorbidities (145, 159–163). Since guidelines are dynamic,
the inclusion of COVID-19 as a minor indication seems
reasonable. However, it would also be judicious to refer to the
spectrum of diseases whereby women with severe COVID-19
are included in the group of patients with major indications
for anticoagulation such that they would receive six weeks
thromboprophylaxis. This paradigm has been useful in the
most recent literature and serves as a template for applications
to the other disciplines.
Since there is sparse literature regarding the guidance of
thromboprophylaxis and treatment of the peripartum COVID19 patient, surgeons must rely on consensus recommendations
from interim guidelines. These recommendations for
peripartum anticoagulation and thromboprophylaxis have
been extrapolated from the COVID-19 literature for nonpregnant patients. Interim guidelines have been published by
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Orthopaedics
Similar to obstetric patients, there is a spectrum of risk for
developing postoperative VTE as a function of COVID-19
illness severity in patients undergoing orthopaedic surgery.
Signiﬁcant literature has demonstrated the beneﬁt of serial
VHAs to predict postoperative VTE (167–169). Therefore, for
a disease which, by its very nature presents with a
hypercoagulopathic state manifested clinically by increased
VTEs and arterial thromboses, the use of VHAs in this
COVID-19 population is a logical extension. While consensus
recommendations have been proposed to optimize safety for
patients undergoing elective surgery after previously being
diagnosed with COVID-19, adjunctive VHAs may enhance
these guidelines to better predict VTE and guide anticoagulant
therapy postoperatively (131, 170–172).
Early intervention tends to be optimal for fracture ﬁxation, but
timing of surgery is historically complicated in patients with
hemostatic derangement such as that which is induced in the
post-COVID-19 patient. Decreased time between hip fracture
and surgery correlates with decreased morbidity and mortality.
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TABLE 2 | Society recommendations on timing of surgery and thromboprophylaxis in acute and convalescent COVID-19 patients. Note this table is not exhaustive,
but reﬂects the diverse and heterogeneous recommendations regarding the timing of surgery and anticoagulation for this patient population.
Discipline
Anesthesia

Association
American Society of Anesthesiologists (13)

Recommendations

• Timing of elective surgery should be delayed based on the symptoms and severity of
acute COVID-19 illness. From time of diagnosis:

• Four weeks for an asymptomatic patient or those recovering from mild, nonrespiratory symptoms

• Six weeks for a patient with respiratory symptoms who was not hospitalized
• Eight to 10 weeks for a symptomatic patient who is immunocompromised, diabetic,
or was hospitalized

• Twelve weeks for a patient who was admitted to an ICU for COVID-19 complications
Obstetrics

American College of Obstetricians and
Gynecologists (124)

• Surgery may be delayed when a patient’s health would not be harmed.
• Thrombosis risk may be increased with COVID-19 infection
• Pregnant patients hospitalized for severe COVID-19 receive prophylactic dose
anticoagulation unless contraindicated

American Society for Reproductive Medicine
(125)

• Procedures should not be delayed if patient health is at risk; triage into four periods
•
•
•
•

Royal College of Obstetricians and
Gynecologists (126)

of surgery:
Cannot be delayed (e.g., hysteroscopy)
Delay up to four weeks (e.g., colposcopy, LEEP)
Delay four to twelve weeks (e.g., TVUS, vulvar biopsy)
Delay beyond twelve weeks (e.g., Botox)

• Thromboprophylaxis should still be offered and administered as normally indicated
during the COVID-19 pandemic, should be continued if patient contracts COVID-19

• Pregnant women with COVID-19 should be given prophylactic LMWH, unless birth is
expected within 12 hours or there is signiﬁcant risk of hemorrhage

• Pregnant women hospitalized with COVID-19 should be offered thromboprophylaxis
for 10 days following discharge and longer with thrombophilic co-morbidities

• Postpartum patient hospitalized for COVID-19 infection should be offered
thromboprophylaxis during hospitalization and for at least 10 days after discharge,
and up to 6 weeks of thromboprophylaxis for thrombophilic co-morbidities
• Avoid general anesthesia for at least 7 weeks after COVID-19 infection
Orthopaedics

General Surgery

American Academy of Orthopedic Surgeons
(127)

• Reschedule elective surgery for individuals with ongoing COVID-19
• Delay elective surgery based on local capacity to care for COVID-19 patients

American Association for Hand Surgery (128)

• Delay surgery based on local capacity to care for COVID-19 patients

American Association of Hip and Knee
Surgeons (129)
American Orthopaedic Association (130)

• Prioritize surgery based on clinical need

European Hip Society and European Knee
Associates (131)

• For infected otherwise healthy individuals, delay elective arthroplasty by 6 weeks
• For infected patients with one or more co-morbidity, delay surgery by 8 weeks

American Society for Metabolic and Bariatric
Surgery (132)

• Delay surgery based on risk factors, local viral prevalence, and institutional resource

American Society of General Surgeons (133),
American College of Surgeons (134, 135)

• Prioritize surgery based on risk factors and patient beneﬁts on an individual basis
• Discernment process is streamlined at an institutional level, with ﬁnal input coming

• Delay surgery based on clinical need and institutional resource availability

availability on an individual basis

from the surgeon

• Defer to Centers for Medicare & Medicaid Services (CMS) tiered framework for
urgency of procedures based upon Elective Surgery Acuity Scale (ESAS)
Centers for Medicare & Medicaid Services
(CMS) (136)

• Three-tiered system to decide whether to postpone surgery based upon two factors:
acuity of procedure and the health of the patient

• Tier 1, low acuity surgery – postpone (e.g., carpal tunnel release, routine
colonoscopy)

• Tier 2, intermediate acuity surgery – consider postponing (e.g., arthroplasty, elective
angioplasty + stent)

• Tier 3, high acuity surgery – do not postpone (e.g., trauma, cancers, neurosurgery)
(continued)
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TABLE 2 | Continued
Discipline

Association
American Society of Transplant Surgeons (137)

Recommendations

• A positive PCR test should result in delay of procedure
• A period of 2-4 weeks of negative serology is required for waitlist reactivation of
immunosuppressed candidates after COVID-19 contraction

Society of American Gastrointestinal
Endoscopic Surgeons (138)

• Delay surgery based on risk factors (age and potential comorbidity) and institutional
resource availability

• Enhanced CMS guidelines: for example, for T3 or higher gastric cancers neoadjuvant
chemotherapy can be an alternative, allowing surgical delay up to 3-4 months but is
dependent upon the rate of disease progression
Neurosurgery

European Association of Neurosurgical
Societies (139)

•
•
•
•

Cardio-toracic &
Vascular Surgery

Canadian Society of Cardiac Surgeons (140)

• Details three phases of ‘ramping up’ cardiac surgery case volume based on hospital

Elective Surgery Acuity Scale (ESAS) adapted to neurosurgical procedures
There are three tiers of procedures:
Tier 1, low acuity surgery: postpone (e.g., benign intracranial tumors)
Tier 2, intermediate acuity surgery: postpone if possible (e.g., AV malformation,
unruptured aneurysm)
• Tier 3, high acuity surgery: do not postpone (e.g., malignant brain or spine tumor)

capacity

• Emphasizes which surgical procedures are emergent or can be delayed for medical
or percutaneous interventions
Society of Thoracic Surgeons (141)

• Describes four tiers of operative capacity, wherein each tier details essential
procedures and which should be deferred

Society for Vascular Surgery (142)

• Links to worldwide society guidelines are provided including adaptations of CMS
and ACS protocols

European Society for Vascular Surgery
Management Guidelines for Acute Limb
Ischemia (ALI) (143)

• Open and endovascular interventions for acute limb ischemia (ALI) for patients with
COVID-19 have a mortality rate of 20.4%

• Therapeutic anticoagulation with intravenous unfractionated heparin should be
•
•
•
•

Plastic Surgery

American Society of Plastic Surgeons (144)

provided for ALI unless signiﬁcant contraindications, serious bleeding within
48 hours, or recent surgery
No high-quality data to suggest open vs. vascular intervention for COVID-associated
ALI
Coagulopathy, hyperinﬂammation, and endothelial injury increase morbidity postvascular surgery
Heparin resistance is common
COVID-19 patients have abnormal coagulation patterns which may interfere with
adequate therapeutic anticoagulation

• Focuses mostly on transmissibility precautions
• Defers to CMS guidelines for resuming elective practice

• Abbreviations: ACS, American College of Surgeons; ALI, acute limb ischemia; AV, arteriovenous; CMS, Centers for Medicare & Medicaid Services; COVID-19, coronarvirus
disease 2019; ESAS, elective surgery acuity scale; ICU, intensive care unit; LEEP, loop electrosurgical excision procedure; LMWH, low molecular weight heparin; PCR,
polymerase chain reaction; TVUS, transvaginal ultrasound.

in orthopaedic pathology, COVID-19 prognosis, surgical
ﬁtness, and desire to undergo the procedure with regards to
evolving risks and beneﬁts. Robust appraisal during the
preoperative period to evaluate ﬁtness for surgery is necessary
to mitigate the risk of postoperative complications and
decrease strain on postoperative intensive care units (170).
Speciﬁc orthopaedic society recommendations are outlined
in Table 2. The American Association for Hand Surgery
suggests delaying surgery based on the capacity to care for
COVID-19 patients rather than postoperative prognosis (128).
The American Orthopaedic Association offers broad
suggestions regarding delay of surgery based on clinical need

However, correct timing of surgery in patients diagnosed with
COVID-19 is difﬁcult to assess (173). As an example of the
heterogeneity of recommendations, it has been noted that a
delay in fracture ﬁxation of up to three months postinjury is
acceptable, allowing for the risks of delayed surgery to be
weighed against the risks of early fracture ﬁxation performed
during early post-COVID-19 prognosis (170).
Therefore, it is generally recommended that clinicians
address each post-COVID-19 case individually and tailor a
unique treatment plan for each patient based on their severity
of injury and COVID-19 prognosis (172, 173). Patients
waiting for elective orthopaedic surgery need to be reassessed
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TABLE 3 | Orthopaedics Elective Surgery Acuity Scale (ESAS). All candidates for surgery should be assessed for surgical ﬁtness on an individual basis. This is an
example ESAS and not comprehensive. Procedure acuity for the individual patient may shift among tiers based upon acuity of illness, severity of COVID-19 infection
and coagulopathy, and hospital surgical capacity (135). For speciﬁc length of operative delay, please see the text and Association of Anesthesiologists guidelines
(13).
Tier 1
Low Acuity
Delay
Trauma

n/a

Tier 2
Intermediate Acuity
Delay if possible
Fractures >4 weeks old
Chronic infections

Tier 3
High Acuity
Do not delay
All new fractures
Acute infections
Malunion/nonunion
Patellar or quad tendon rupture

Orthopaedic Oncology

Benign tumor biopsy and removal

Aggressive benign tumor (e.g., giant cell tumor)

Pathologic fracture

Joints

Elective joint arthroplasty

Chronically infected hardware

Hip fracture or dislocation
Acutely infected hardware

surgery where postponement is not an option (136). Table 4
speciﬁcally deﬁnes example surgical procedures based on this
three-tiered system.
With regards to transplant surgery, COVID-19 infection
following organ implantation is associated with increased
mortality (176, 177). Pre-vaccination prior to transplant has
been suggested to reduce the risk of mortality (178). In the
context of receiving an organ from a COVID-19 positive
donor, there is growing evidence that viral transmission from
abdominal organs is a nearly negligible risk (179). This has
led to a call for increased use of COVID-19 positive donors
without evidence of systemic disease, as the low risk of
transmission does not appear to outweigh the potential
lifesaving beneﬁt from organ transplantation (180). However,
a positive PCR test in a recipient should delay the procedure,
and a delay of at least two to four weeks of negative serologies
is required for waitlist reactivation of immunosuppressed
candidates after COVID-19 contraction.
The Society of American Gastrointestinal Endoscopic
Surgeons has provided speciﬁc guidelines for gastrointestinal
cancers similar to the ESAS (138). A large study of over four
million cancer patients found that most oncological
procedures can be delayed by four weeks without a signiﬁcant
impact on patient morbidity or mortality (181, 182). However,
a patient’s age and comorbidities are critical for weighing the
relative beneﬁt and risk of potentially exposing the patient to
COVID-19 as opposed to choosing alternative options. The
resources available to the surgeon must also be considered,
since the pandemic has caused large ﬂuctuations in patient
acuity, volume, and hospital resources (183). In COVID-19
positive patients with primary or secondary cancer, elective
liver or adrenal resection should be delayed until patients fully
recover from acute COVID-19. In cases of jaundice or
infection, percutaneous transhepatic biliary drainage (PTBD)
or endoscopic retrograde cholangiopancreatography (ERCP)
should be ﬁrst implemented as a bridge therapy (184).

and institutional availability (130). Most of these orthopedic
organizations do not have speciﬁc guidelines for delaying
surgery to reduce the incidence of VTEs. However, the
European Hip Society and European Knee Associates
recommend delaying arthroplasty for six weeks following
infection for otherwise healthy individuals, and for infected
individuals with one or more comorbidities delaying the
surgery for at least 8 weeks (131). When compared to
anesthesia and non-orthopaedic society recommendations, the
recommendations from European societies seem the most
judicious provided the well-recognized increases in mortality
and VTE complications associated with post-COVID-19
elective surgeries (13, 134). An example ESAS for delaying
procedures is provided in Table 3.

General Surgery
The COVID-19 pandemic resulted in a signiﬁcant reduction of
general surgical procedures, including procedures for both
benign and malignant diseases. While elective surgery for
benign disease was intentionally halted during the pandemic,
the reduction in procedures for malignancies was likely an
unintentional consequence of reduced patient access to clinical
examinations and diagnostic testing as a result of limited
capacity of healthcare systems (174).
At the beginning of the pandemic, it was recommended that
emergent cases be individualized based on patient risk, urgent
cases be delayed at least until COVID-19 infection clears, and
elective cases not be performed and potentially delayed for
months (175). Emergency surgery was performed on patients
regardless of their COVID-19 infection status.
The ACS and the American Society of General Surgeons
initially published guidelines based on risk factors and patient
beneﬁts related to SARS-CoV-2 transmissibility during acute
infection. These guidelines are heterogeneous and do not
speciﬁcally address hemostatic complications related to elective
and acute surgery during acute and convalescent COVID-19
(133, 134). These two associations adopted the CMS 3-tiered
framework for urgency of procedures based on the ESAS (134,
136). This three-tiered system is deﬁned by Tier 1, elective
surgery which is to be postponed; Tier 2, intermediate acuity
surgery postpone if possible; and Tier 3, indications for acute
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Neurosurgery
The literature concerning timing of neurosurgical procedures
has mostly considered SARS-CoV-2 transmissibility and
healthcare worker safety (185–188). For example, it has been
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TABLE 4 | General Surgery Elective Surgery Acuity Scale (ESAS). All candidates for surgery should be assessed for surgical ﬁtness on an individual basis. This is
an example ESAS and not comprehensive. Procedure acuity for the individual patient may shift among tiers based upon acuity of illness, severity of COVID-19
infection and coagulopathy, and hospital surgical capacity (134–136). For speciﬁc length of operative delay, please see the text and Association of
Anesthesiologists guidelines (13).
Tier 1
Low Acuity
Delay

Tier 2
Intermediate Acuity
Delay if possible

Tier 3
High Acuity
Do not delay

Abdominal/
pelvic

Acute hemorrhoidal thrombosis/
necrosis

Perianal or perirectal abscess
Soft tissue infections
Appendicitisa
Percutaneous cholecystectomy for severe
acute cholecystitis
Diverticulitis

Bariatric

Primary gastric bypass
Gastric sleeve
Gastric band
Duodenal switch

Revisions for dysphagia
Severe GERD
Slipped band

Anastomotic leak
Gastric perforation
Obstruction

Breast

Excision of benign lesions
Duct excisions
Discordant biopsies likely to be
benign
Clinical stage T1N0 ER+/PR
+/HER2- tumors

Any cancer that can receive neoadjuvant or hormonal
therapy prior to surgery

Neoadjuvant patients ﬁnishing treatment
Triple negative or HER2 + patients
Excision of malignant recurrence
Discordant biopsies likely to be malignant
Clinical stage T2 or N1 ER+/PR+/HER2tumors

Colorectal
cancer

Prophylactic indications for
hereditary conditions
Large, benign appearing
asymptomatic polyps
Small, asymptomatic carcinoids

Locally advanced resectable colon cancer viable to
neoadjuvant chemotherapy
Rectal cancer with clear evidence of downstaging from
neoadjuvant chemoradiation therapy

Perforated, obstructed, septic, or actively
bleeding cancers
Malignant polyps

Abbreviations: ER, estrogen receptor; GERD, gastroesophageal reﬂux disease; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.
a
Evolving data suggests some careful selection for antibiotic treatment over surgery for uncomplicated appendicitis without appendicolith.

demonstrated that tracheostomies may be safely delayed two
weeks, whereas craniectomy and tumor resections, as well as
evacuation of subdural hematomas, need to be evaluated on a
case-by-case basis (188, 189). Surgical treatment of chronic
subdural hematoma, a usually successful intervention with a
reported mortality rate of 3.7%, has a markedly increased
mortality risk in COVID-19 positive surgical patients (190).
Further investigation attributes multiple factors to this
mortality rate, including thrombocytopenia, immune system
impairment, and interstitial pneumonia progression postsurgery (191).
Like other surgical societies, there is heavy reliance on the
modiﬁed ESAS for determining the timing of neurosurgical
procedures for COVID (139). A similar 3-tiered system has
been proposed regarding low, intermediate, and high acuity
indications for neurosurgical intervention. Examples of surgeries
that are divided into these three tiers are Tier 1, benign
intracranial tumors which are low acuity; Tier 2, unruptured
cerebral aneurysms and AV malformations as intermediate
acuity; and Tier 3, malignant brain and spinal tumors for high
acuity surgery where postponement is not an option (139).
Table 2 and 5 summarizes current neurosurgical guidelines
regarding the timing of surgery for COVID-19 patients.

guidelines for determining the timing of surgery during the
COVID-19 pandemic (140, 141). The cardiothoracic
guidelines have also beneﬁted from the cardiology literature,
which recommends adherence to standard anticoagulation
procedures for patients with post-acute sequelae of COVID-19
who are undergoing percutaneous coronary intervention with
or without angioplasty for ST segment elevation myocardial
infarcts (192). During the acute period of COVID-19
infection, adherence to standard heparin boluses, anti-platelet,
and intravenous and oral anti-factor agents is recommended
without any change (193). For those patients whose
intervention is complicated by a hypercoagulable state,
treatment should be titrated with a personalized medicine
approach and the use of VHAs to guide anticoagulation has
been suggested (194–196). Acutely ill patients with severe
coronary artery disease and valvular pathology not amenable
to non-surgical interventions can either be operated
immediately or temporized with a left ventricular assist device,
intra-aortic balloon pump, or extracorporeal membrane
oxygenation while waiting for the cytokine storm to abate if
clinically possible (197). These guidelines are heterogeneous
and likewise founded on the ASA and ACS three-tiered
system of classifying patients with COVID-19 who require
surgery (13, 134).
Provided the protracted nature of this pandemic, cardiac
surgery programs must continue to proactively manage every
patient on their waitlist with re-expansion of case volumes.

Cardiothoracic and Vascular Surgery
Cardiothoracic and vascular surgery society guidelines have
likewise adapted the CMS recommendations as well as ESAS
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TABLE 5 | Neurosurgery Elective Surgery Acuity Scale (ESAS). All candidates for surgery should be assessed for surgical ﬁtness on an individual basis. This is an
example ESAS and not comprehensive. Procedure acuity for the individual patient may shift among tiers based upon acuity of illness, severity of COVID-19 infection
and coagulopathy, and hospital surgical capacity (135, 139). For speciﬁc length of operative delay, please see the text and Association of Anesthesiologists
guidelines (13).
Tier 1
Low Acuity
Delay

Tier 2
Intermediate Acuity
Delay if possible

Tier 3
High Acuity
Do not delay

Neurooncology

Benign, asymptomatic intracranial tumors

Benign, symptomatic intracranial
tumors

Malignant brain or spine tumors

Spine

Lumbar stenosis w/o FNDs
Laminectomy discectomy w/o FNDs

Kyphoplasty
Laminectomy discectomy w/ FND

Progressive cervical /thoracic myelopathy
Cauda equina or conus medullaris syndrome

AV malformation
Unruptured aneurysm

Ruptured aneurysm coiling or clip
Chronic subdural hematoma

Neurovascular
Peripheral
nerve

Carpal tunnel release

Peripheral nerve release

Brachial plexus injury

Other

Microvascular decompression of cranial
nerves

DBS for Parkinson’s disease
Refractory epilepsy

Post-traumatic elevated ICP not controlled by conservative
measures

Abbreviations: DBS, deep brain stimulation; FND, focal neurologic deﬁcit; ICP, intracranial pressure.

procedures for ALI is a function of the acuity of the limb
ischemia and its relation to the hemostatic derangement
present in the COVID-19 patient. There is no high-quality
data to suggest that either open or vascular intervention is the
preferred treatment ALI. It has been noted that a heparin
resistance is in acute COVID-19 illness is common, while at
the same time, the capricious nature of the cytokine storm
causes the COVID-19 patient to have abnormal coagulation
patterns. This interference with therapeutic anticoagulation
requires frequent monitoring of not only aPTT and anti-Xa
levels, but also with VHAs (17, 20–23, 108).

Aspects of this management have been divided into three
separate tiers of so-called ‘ramp up’ levels which determine
the timing of surgery based on a combination of return to
surgical case volume and acuity of indication for
cardiothoracic surgery (141, 198).
The Canadian Cardiothoracic Society has described the
following criteria: For ramp up phase one where the surgical
volume is increased 0-25%, the patients who should avoid
surgery when possible include frail elderly patients (clinical
frailty score > 4) and vulnerable co-morbid patients including
those with renal insufﬁciency, poor ejection fractions, and
advanced congestive heart failure. Overall, in a phase one
scenario, the cardiothoracic surgeon should attempt to avoid
complex procedures including re-operative surgery while
prioritizing CABG, isolated valve procedures, and less complex
procedures to maximize patient ﬂow. There should be an
emphasis on patients with aortic stenosis and coronary artery
disease with prognostic beneﬁt, such as critical aortic stenosis
and left main coronary disease. In the ramp up phase two,
where surgical volume is increased 25-50%, inpatient urgent
and emergency surgeries should be continued with broadening
inclusion of appropriately prioritized outpatients. Ramp up
phase three occurs with 50-100% increase in capacity with a
return to normal outpatient services while continuing to
prioritize those as greatest risk such as asymptomatic and
severe mitral regurgitation, atrial septal defect or patent
foramen ovale surgery, and asymptomatic aneurysm with
demonstrated stable size.
In the thoracic surgery literature, a four-tier system of patient
triage has been recommended by The Society of Thoracic
Surgeons COVID-19 Task Force and the Workforce for Adult
Cardiac and Vascular Surgery. For consistency here, we
provide a three-tiered ESAS in Table 6.
Systemic anticoagulation with intravenous unfractionated
heparin should be provided for all patients with acute limb
ischemia (ALI). The performance of endovascular or open
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Plastic, Oculoplastic, & Reconstructive
Surgery
Similar guidelines based on the CMS and ESAS criteria have
been adapted to the oculo/plastic and reconstructive
procedures (199, 200). These guidelines are based on the
three-tiered system which also incorporates the supply and
demand for elective and acute surgeries and the acuity of the
surgical intervention required. Of all specialties, the
oculoplastic international societies have the most exhaustive
list of procedures incorporated within the context of the
three-tiered system since most of their surgeries are elective
(201). These are summarized in Table 7 below.
Of particular importance for this group of patients is the
viability of microvascular ﬂaps which, because of the
hypercoagulability mediated by the immuno-thrombotic
derangements that are part of CAC, require evaluation by the
surgeon for the timing of surgery and the risk of ischemic
ﬂap loss. For example, criteria for the administration of
continuous unfractionated heparin have been suggested for
microvascular free ﬂaps after head and neck cancer excision
(202, 203). Recent publications have demonstrated the use of
VHAs in guiding anticoagulation therapy to maintain
vascular patency of microvascular vessels in ﬂap surgery and
reconstruction (204).
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TABLE 6 | Cardiothoracic & Vascular Elective Surgery Acuity Scale (ESAS). All candidates for surgery should be assessed for surgical ﬁtness on an individual basis.
This is an example ESAS and not comprehensive. Procedure acuity for the individual patient may shift among tiers based upon acuity of illness, severity of COVID19 infection and coagulopathy, and hospital surgical capacity (135, 140, 141). For speciﬁc length of operative delay, please see the text and Association of
Anesthesiologists guidelines (13).
Tier 1
Low Acuity
Delay

Tier 2
Intermediate Acuity
Delay if possible

Tier 3
High Acuity
Do not delay

Aortic aneurysm

AAA < 6.5 cm

AAA or TAA > 6.5 cm

Ruptured or symptomatic AAA or TAA
Associated with infection or prosthetic infection

Bypass graft
complications

Asymptomatic bypass graft/
stent stenosis

Revascularization for high grade re-stenosis of
previous intervention

Infected arterial prosthesis

Carotid

Asymptomatic carotid artery
stenosis

Cardiac

Asymptomatic mitral
regurgitation
Isolated arrhythmia procedure

Symptomatic mitral regurgitation
PFO or ASD surgery

Severe CAD

Dialysis

n/a

Fistula revision for malfunction/ steal
Fistulagram for malfunction
AV ﬁstula and graft placement for dialysis (ESRD,
CK4, and CK5 only)

Infected dialysis access
Tunneled dialysis cathetersa
Thrombosed or nonfunctional dialysis access
Fistula revision for ulceration

Symptomatic carotid stenosis: TCAR and CEA
Symptomatic aortic stenosis

Mesenteric

n/a

Chronic mesenteric ischemia

Symptomatic acute mesenteric ischemia

Peripheral vascular
disease

Surgical procedures for
claudication

Chronic limb threatening ischemia

Acute limb ischemia

Thoracic outlet
syndrome

Neurogenic TOS

TOS, venous

Symptomatic venous TOS with acute occlusion
and marked edema
TOS, arterial with thrombosis

Venous

Varicose veins
IVC ﬁlter removal
Asymptomatic May Thurner
syndrome

Procedures for ulcerations secondary to venous
disease
IVC ﬁlter placement

Acute iliofemoral DVT with phlegmasia

Abbreviations: AAA, abdominal aortic aneurysm; ASD, atrial septal defect; AV, arteriovenous; CAD, coronary artery disease; CEA, carotid endarterectomy; CK, chronic kidney
disease; DVT, deep vein thrombosis; ESRD, end stage renal disease; IVC, inferior vena cava; PFO, patent foramen ovale; TAA, thoracic aortic aneurysm; TCAR, transcarotid
artery revascularization; TOS, thoracic outlet syndrome.
a
May be placed in emergent situations which allow for postponement of the deﬁnitive ﬁstula or graft surgery.

TABLE 7 | Plastic, Oculoplastic, and Reconstructive Elective Surgery Acuity Scale (ESAS). All candidates for surgery should be assessed for surgical ﬁtness on an
individual basis. This is an example ESAS and not comprehensive. Procedure acuity for the individual patient may shift among tiers based upon acuity of illness,
severity of COVID-19 infection and coagulopathy, and hospital surgical capacity (199–201). For speciﬁc length of operative delay, please see the text and
Association of Anesthesiologists guidelines (13).
Tier 1
Low Acuity
Delay

Tier 2
Intermediate Acuity
Delay if possible

Tier 3
High Acuity
Do not delay

Oculoplastic

Blepharoplasty
Slow-growing BCC
Chalazion drainage
Ptosis repair

Cutaneous malignancy other than slow-growing
BCC
Amblyopia in an infant
Orbital exploration for non-vision threatening
conditions

Canthotomy
Orbital abscess drainage
Optic nerve sheath fenestration
Dacryocele decompression in a neonate

Plastic &
Reconstructive

Revision reconstructive breast
surgery
Cosmetic surgery

Non-melanoma skin cancer biopsy/resection/
grafting
ORIF of maxillofacial fractures

Digit replantation
Skull base reconstruction
3rd-degree burns
Fasciotomy for acute compartment
syndrome
Necrotizing fasciitis debridement

Abbreviations: BCC, basal cell carcinoma; ORIF, open reduction internal ﬁxation.
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University (South Africa): N19/03/043, project ID 9521.
Conﬁrmation of omicron variant: N20/04/008_COVID-19.
Ethics approval for the inclusion of the microclot micrographs
in this review paper was received from the Ethics committee
of Stellenbosch University (HREC2-2022-24525).

CONCLUSION
The pathophysiological derangements of patients infected with
SARS-CoV-2 require an understanding of the fundamental
endotheliitis and immunothrombotic crosstalk causing
ﬁbrinolytic shutdown. For the surgeon who must confront an
acutely ill patient with COVID-19, important decisions must
be made regarding not just the timing of surgery, but also
the nature of anticipating the thrombohemorrhagic
complications of CAC and whether the patients are fully or
prophylactically anticoagulated (205). For those patients who
require elective surgery, a large study suggests a delay of up
to seven weeks for elective surgery following SARS-CoV-2
infection, a guideline which has recently been adopted by
specialty-speciﬁc societies (10). Yet, other studies have found
abnormal hypercoagulability biomarkers up to six months
after COVID-19 recovery, indicating potentially increased
risk for some patients past seven weeks (81, 89–93). Reﬁned
use of these biomarkers for risk-beneﬁt analysis can help to
determine the most favorable time for surgery (7). In regard
to the administration of thromboprophylaxis and full
anticoagulation in the convalescent COVID-19 postoperative
patient, certain biomarkers can potentially be used in a
personalized-based medicine approach (77). More studies are
needed to analyze biomarkers and physiologic derangements
in COVID-19 recovery patients focusing on how these
proﬁles forecast postoperative outcomes. VHAs have
historically been used to proﬁle postoperative patients at
risk for VTE, and may help guide surgeons with timing
of elective surgery, thromboprophylaxis, and full anticoagulation in this patient population (113–116). As the
pandemic evolves, one can anticipate changing guidelines
that may vary based on the COVID variant with accruing
data on managing elective and acute surgery in this unique
group of patients.
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